Matrix Global Advisors
  • Home
  • About
  • News
  • Reports
  • Contact
  • Follow
  • Follow
Alex Brill on Single-Payer Health Care System and Drug Costs

Alex Brill on Single-Payer Health Care System and Drug Costs

Jan 12, 2024 | Interviews

Alex Brill is a senior fellow at the American Enterprise Institute (AEI), where he studies the impact of tax policy on the US economy as well as the fiscal, economic, and political consequences of tax, budget, health care, retirement security, and trade policies.

New MGA Analysis Finds Drug Rebates Not Associated with List Price Increases

New MGA Analysis Finds Drug Rebates Not Associated with List Price Increases

Jan 10, 2024 | Analysis

In a new report, MGA examines the role of rebates among a subset of prescription drugs with the biggest price hikes between 2018 and 2023. 

Alex Brill mentioned on MSN

Alex Brill mentioned on MSN

Jan 6, 2024 | Interviews

If the Supreme Court rules in their favor, it could open the door to reshaping the country’s tax code.

Alex Brill Speaks on Consequences of Proposed PBM Constraints

Alex Brill Speaks on Consequences of Proposed PBM Constraints

Dec 14, 2023 | Events

In December, MGA CEO Alex Brill participated in a RealClearPolitics event looking at the negative consequences of limiting the business practices of PBMs.

Implications of Cannabis Legalization for the US Federal Budget

Implications of Cannabis Legalization for the US Federal Budget

Oct 24, 2023 | Analysis

Federal legislation to legalize, regulate, and tax cannabis could have significant impacts on the federal budget.

« Older Entries
Next Entries »
  • Analysis (54)
  • Books (3)
  • Commentary (15)
  • Events (21)
  • Interviews (60)
  • News (55)
  • Op-Eds (100)
  • Press Releases (4)
  • Testimony (21)
  • Government’s Drug Negotiation Program
    Diminishing Returns from the Government’s Drug Negotiation ProgramJanuary 29, 2026
  • ACA Tax Credit Extension Matter
    Would Senate Passage of an ACA Tax Credit Extension Matter?January 14, 2026
  • PBMs Pass Through Rebates
    MGA Brief Examines State and Federal PBM MandatesDecember 1, 2025
  • FDA Moves to Facilitate Biosimilar Development
    FDA Moves to Facilitate Biosimilar DevelopmentOctober 30, 2025
  • How Pharmaceutical Tariffs Will Affect US Health Care Costs
    How Pharmaceutical Tariffs Will Affect US Health Care CostsSeptember 26, 2025
  • Quantifying the economic impact of healthcare distributors
    MGA Releases New Report Quantifying the Economic Impact of Healthcare DistributorsSeptember 17, 2025
  • Unsung Hero of the OBBBA
    The Unsung Hero of the OBBBA: Permanent ExpensingAugust 20, 2025
  • Alex Brill Interviewed by Biosimilars Review & Report
    Alex Brill Interviewed by Biosimilars Review & ReportAugust 6, 2025
  • Medicare Price Negotiations and Drug Competition
    MGA Releases New White Paper on Medicare Price Negotiations and Drug CompetitionJuly 14, 2025
  • effects of 304B
    The 340B Program’s Negative Impact on Pharmaceutical InnovationJune 5, 2025
© Copyright 2022 Matrix Global Advisors | Design By DreamBig Creative
MGA
  • Home
  • About
  • News
  • Reports
  • Contact